Breast Cancer for Surgeons — Screening, Triple Assessment, Receptors, BCT versus Mastectomy, Axillary De-escalation, EBCTCG Systemics

The one-line answer

Breast cancer is the most commonly diagnosed cancer worldwide, and the surgeon's job is local control with the least morbidity that the trials allow: triple assessment with core-biopsy tissue, breast conservation plus radiotherapy when margins are clear, sentinel-node staging with dissection omitted only inside tested eligibility, and biology-driven systemic therapy anchored in EBCTCG meta-analyses and the HERA, TAILORx, KATHERINE, and OlympiA trials.^{[1][7][8][13][22][26]}

A 52-year-old woman with a screen-detected 22 mm mass, a clinically negative axilla, and a core biopsy showing ER-positive HER2-negative carcinoma walks the whole topic in one patient: confirm triple assessment, offer breast-conserving surgery with sentinel-node biopsy, check no ink on tumour, then let receptors, stage, and a genomic assay decide endocrine therapy with or without chemotherapy.^{[4][7][9][24]}

Burden — why examiners start here

Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%).^[1] Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers.^[1] Quote the displacement first and the mortality rank second: commonest diagnosed, fifth for mortality share — the gap between the two is the screening and systemic-therapy story the rest of this topic tells.^[1]

Among all US women, breast cancer is the second most common cancer and the second most common cause of cancer death, and in 2023 an estimated 43,170 women died of breast cancer.^[2] Germline BRCA1 or BRCA2 status changes management beyond risk: adjuvant olaparib is tested in HER2-negative early breast cancer with BRCA1 or BRCA2 germline pathogenic or likely pathogenic variants and high-risk clinicopathological factors after local treatment and neoadjuvant or adjuvant chemotherapy.^[28] Detailed risk-factor weights, reproductive-history arithmetic, and risk-reducing operation thresholds sit outside this topic's verified set and stay fenced to genetics and prevention topics — this topic claims only the burden numbers and the BRCA-eligibility link above.^[1][28]

Screening — USPSTF 2024 and Marmot honesty

The USPSTF recommends biennial screening mammography for women aged 40 to 74 years (B recommendation).^[2] The USPSTF concludes with moderate certainty that biennial screening mammography in women aged 40 to 74 years has a moderate net benefit.^[2] For women 75 years or older, the USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening mammography (I statement).^[2] Supplemental screening with breast ultrasonography or MRI in women with dense breasts on an otherwise negative mammogram gets the same insufficient-evidence verdict.^[2]

The consent counterweight comes from the UK Independent Panel: in a meta-analysis of 11 randomised trials, the relative risk of breast cancer mortality for women invited to screening compared with controls was 0.80 (95% CI 0.73 to 0.89), a relative risk reduction of 20%.^[3] Overdiagnosis — cancers detected at screening that would not otherwise have become clinically apparent in the woman's lifetime — ran at 11% (95% CI 9 to 12) of cancers diagnosed in the invited group in the long term, and 19% (15 to 23) during the active screening period.^[3] The Panel focused on the UK setting, where women aged 50 to 70 years are invited to screening every 3 years.^[3] The viva-ready pairing is therefore biennial from 40 to 74 per USPSTF against 3-yearly from 50 to 70 per the UK programme, with the 20% mortality reduction and the 11% overdiagnosis figure quoted in the same breath.^[2][3]

Triple assessment — tissue before decisions

All patients presenting with a symptomatic breast lump are assessed by means of triple assessment: clinical examination, radiology in the form of mammography, and cytology by means of a fine needle aspiration.^[7] The tissue arm has moved on since that description: in 52 patients with clinical or radiological suspicion of cancer, 31 had a definitive diagnosis on fine needle aspiration (sensitivity 60%) compared with 50 of 52 on core biopsy (sensitivity 96%).^[7] Modern practice is therefore triple assessment with core-biopsy tissue — histology plus grade plus ER, PR, and HER2 — before any definitive surgical or systemic decision, because no operation or drug sequence is defensible without receptor status.^[4][5][7] Mammographic microcalcification patterns, ultrasound-versus-MRI selection, and reporting-lexicon detail stay fenced to breast imaging — this topic claims only the triple-assessment discipline and the core-biopsy sensitivity numbers.^[7]

Receptors — the 1% line and the 2+ reflex

Breast cancer samples with 1% to 100% of tumour nuclei positive should be interpreted as ER positive.^[4] A sample is considered ER negative if fewer than 1% or 0% of tumour cell nuclei are immunoreactive.^[4] The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy.^[4] The trap sits in between: there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive, and samples with these results should be reported using a new reporting category, ER Low Positive.^[4] ER-low-positive disease is technically positive but behaves closer to ER-negative — do not promise tamoxifen benefit without that nuance, because the EBCTCG tamoxifen benefit is essentially confined to ER-positive disease and ER status was the only recorded factor importantly predictive of the proportional reductions.^[4][20]

HER2 reporting runs on immunohistochemistry first: IHC 2+ is defined as invasive breast cancer with weak to moderate complete membrane staining observed in more than 10% of tumour cells.^[5] An IHC 2+ result is the reflex trigger — if the initial HER2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 test may (not "must") be ordered on the excision specimen based on specific clinical criteria.^[5] HER2 overexpression predicts trastuzumab benefit: one year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer, with an unadjusted hazard ratio for an event of 0.54 (95% confidence interval, 0.43 to 0.67).^[5][26] Intrinsic-subtype labels (luminal A/B, HER2-enriched, basal-like) and HER2-low drug thresholds sit outside this topic's verified set and stay fenced to pathology and medical oncology — this topic claims only the ASCO/CAP testing thresholds and the HERA result.^[4][5][26]

Staging — anatomic TNM plus prognostic biomarkers

The AJCC panel recognised the need to incorporate biologic factors — tumour grade, proliferation rate, estrogen and progesterone receptor expression, HER2 expression, and gene expression prognostic panels — into the staging system.^[6] To maintain worldwide value, the tumour staging system remains based on TNM anatomic factors, while the prognostic influence of grade, hormone receptor expression, and HER2 amplification mandated their inclusion into the staging system, with prognostic input from commercially available gene-based assays acknowledged and low Oncotype DX recurrence scores able to alter prognosis and stage.^[6] The eighth edition therefore runs two parallel statements: the anatomic TNM and the prognostic stage group, and the eighth edition remains the worldwide basis for breast cancer staging.^[6] Exact millimetre cutoffs for T and N categories, nodal-burden thresholds, and in-situ handling are AJCC-manual detail fenced out of this topic — quote the anatomic-versus-prognostic split and the biomarker list, and open the manual for the numbers.^[6]

Breast conservation versus mastectomy — B-06 equivalence

No significant differences were observed among total mastectomy, lumpectomy, and lumpectomy-plus-irradiation groups with respect to disease-free survival, distant-disease-free survival, or overall survival at 20 years.^[8] That is the whole conservation argument in one sentence: survival is equivalent, so the operation follows the breast, the margins, and the patient's ability to receive radiotherapy.^[8] Radiotherapy does the local work: the cumulative incidence of recurrent tumour in the ipsilateral breast was 14.3% in women who underwent lumpectomy and breast irradiation, compared with 39.2% in women who underwent lumpectomy without irradiation.^[8] Lumpectomy followed by breast irradiation continues to be appropriate therapy for women with breast cancer, provided that the margins of resected specimens are free of tumour and an acceptable cosmetic result can be obtained.^[8]

Margin practice is no-ink-on-tumour: positive margins (ink on invasive carcinoma or ductal carcinoma in situ) are associated with a two-fold increase in the risk of ipsilateral breast tumour recurrence compared with negative margins, and this increased risk is not mitigated by favourable biology, endocrine therapy, or a radiation boost.^[9] More widely clear margins do not significantly decrease the rate of recurrence compared with no ink on tumour — there is no evidence that wider clearance helps young patients, unfavourable biology, lobular cancers, or extensive intraductal component either.^[9] The use of no ink on tumour as the standard for an adequate margin in invasive cancer in the era of multidisciplinary therapy is associated with low rates of recurrence and has the potential to decrease re-excision rates, improve cosmetic outcomes, and decrease health care costs.^[9] DCIS margin widths, oncoplastic volume-displacement techniques, and reconstruction options stay fenced to their operative topics — this topic claims only the invasive no-ink standard and its evidence base.^[9]

DCIS is treated, not watched: with 10-year follow-up, radiotherapy after local excision for DCIS reduced the risk of local recurrence, with a 47% reduction at 10 years, and all patient subgroups benefited.^[10] The 10-year local-recurrence-free rate was 74% with local excision alone compared with 85% with excision plus radiotherapy.^[10] After breast-conserving surgery for invasive disease, radiotherapy reduced the 10-year risk of any first recurrence from 35.0% to 19.3% (absolute reduction 15.7%) and reduced the 15-year risk of breast cancer death from 25.2% to 21.4% (absolute reduction 3.8%) — after breast-conserving surgery, radiotherapy to the conserved breast halves the rate at which the disease recurs and reduces the breast cancer death rate by about a sixth.^[11] Partial-breast irradiation, boost indications, and post-mastectomy radiotherapy fields stay fenced to radiation oncology — this topic claims only the whole-breast numbers above.^[11]

The axilla — from dissection to de-escalation

Sentinel-node surgery replaced routine dissection in the clinically node-negative axilla: overall survival, disease-free survival, and regional control were statistically equivalent between sentinel-node resection and conventional dissection, and when the sentinel node is negative, sentinel-node surgery alone with no further dissection is an appropriate, safe, and effective therapy.^[12] The 8-year Kaplan-Meier estimates for overall survival were 91.8% (95% CI 90.4 to 93.3) with dissection and 90.3% (88.8 to 91.8) with sentinel-node surgery alone.^[12] Sentinel-node surgery was designed to minimise the side-effects of lymph-node surgery while offering equivalent outcomes — that morbidity-sparing intent is the thread running through every trial below.^[12]

Z0011 tested omission after a positive sentinel node in a narrowly defined population: women with clinical T1-T2 invasive breast cancer, no palpable adenopathy, and 1 to 2 sentinel nodes containing metastases, all treated with breast conservation and systemic therapy.^[13] Five-year overall survival was 91.8% (95% CI 89.1% to 94.5%) with dissection and 92.5% (90.0% to 95.1%) with sentinel-node surgery alone, and among patients with limited sentinel-node metastatic disease treated with breast conservation and systemic therapy, sentinel-node surgery alone compared with dissection did not result in inferior survival.^[13] The median number of nodes removed was 17 with dissection and 2 with sentinel-node surgery alone — the morbidity difference behind the survival tie.^[13] At a median follow-up of 9.3 years, 10-year overall survival was 86.3% in the sentinel-node-alone group and 83.6% in the dissection group (HR 0.85, noninferiority P = .02), and these findings do not support routine use of axillary dissection in this patient population based on 10-year outcomes.^[14] Outside that eligibility — mastectomy patients, palpable disease, heavier sentinel-node burden — omission is untested, and completion dissection remains the default: the trials below do not rescue the ineligible patient.^[13][14]

AMAROS randomised the positive-sentinel-node axilla to dissection or radiotherapy: patients had T1-2 primary breast cancer and no palpable lymphadenopathy, and the primary endpoint was non-inferiority of 5-year axillary recurrence, considered to be not more than 4% for radiotherapy against an expected 2% for dissection.^[15] In the dissection group, 220 (33%) of 672 patients who underwent dissection had additional positive nodes — disease left behind whenever the axilla is not dissected.^[15] Axillary dissection and axillary radiotherapy after a positive sentinel node provide excellent and comparable axillary control, and axillary radiotherapy results in significantly less morbidity — with lymphoedema in the ipsilateral arm noted significantly more often after dissection than after radiotherapy at 1, 3, and 5 years.^[15] The 10-year update fixes the numbers: per intention-to-treat analysis, 10-year axillary recurrence cumulative incidence was 0.93% (seven events) after dissection and 1.82% (11 events) after radiotherapy (HR 1.71), with no differences in overall or disease-free survival — and dissection carried the higher lymphoedema rate in updated 5-year analyses (24.5% versus 11.9%).^[16] Considering less arm morbidity, radiotherapy is preferred over dissection for patients with sentinel-node-positive cT1-2 breast cancer, while quality-of-life scales did not differ by treatment through 5 years.^[16]

INSEMA asks whether even the sentinel biopsy can go: omission of surgical axillary staging was noninferior to sentinel-node biopsy after a median follow-up of 6 years.^[17] The estimated 5-year invasive disease-free survival rate was 91.9% (95% CI 89.9 to 93.5) in the surgery-omission group and 91.7% (90.8 to 92.6) among patients in the sentinel-biopsy group.^[17] This is the de-escalation frontier, not the standard — quote it as a trial result with its follow-up horizon, and keep dissecting outside its population.^[17]

The post-neoadjuvant axilla is a different organ for staging purposes. In Z1071, among women with cN1 disease receiving neoadjuvant chemotherapy who had 2 or more sentinel nodes examined, the false-negative rate was not found to be 10% or less: in 39 patients cancer was missed in the sentinel nodes but found at dissection, a false-negative rate of 12.6%.^[18] SENTINA agrees: in patients converting from cN+ to ycN0, the detection rate was 80.1% and the false-negative rate was 14.2%, and after systemic treatment the procedure has a lower detection rate and a higher false-negative rate compared with sentinel-node biopsy done before neoadjuvant chemotherapy.^[19] Z0011-type omission therefore does not transfer into the post-neoadjuvant setting — stage before systemic therapy whenever the plan allows, and treat the post-treatment sentinel node as a higher-false-negative test.^[18][19]

Endocrine therapy — the EBCTCG numbers

For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31%.^[22] The receptor-relevance analysis sharpens the indication: in ER-positive disease, allocation to about 5 years of tamoxifen substantially reduced recurrence rates throughout the first 10 years (relative risk 0.53 during years 0 to 4 and 0.68 during years 5 to 9), breast cancer mortality was reduced by about a third throughout the first 15 years, and ER status was the only recorded factor importantly predictive of the proportional reductions.^[20] Tamoxifen benefit is therefore an ER-positive-only proposition — the ER-low-positive caveat above applies in full.^[4][20]

In postmenopausal ER-positive disease, 5 years of an aromatase inhibitor beats 5 years of tamoxifen: recurrence relative risks favoured aromatase inhibitors during years 0 to 1 (0.64) and 2 to 4 (0.80), and 10-year breast cancer mortality was lower with aromatase inhibitors than tamoxifen (12.1% versus 14.2%), a reduction of about 15% compared with tamoxifen.^[21] Ovarian-function detail, switching and sequencing schedules, extended-duration decisions, and class toxicities sit outside this topic's verified set and stay fenced to medical oncology — this topic claims only the 5-year head-to-head numbers.^[21]

Chemotherapy and genomic assays — sparing by numbers

About 6 months of anthracycline-based polychemotherapy (for example FAC or FEC) reduces the annual breast cancer death rate by about 38% for women younger than 50 years at diagnosis and by about 20% for those aged 50 to 69, largely irrespective of tamoxifen use, ER status, nodal status, or other tumour characteristics.^[22] Adding four separate cycles of a taxane to a fixed anthracycline-based regimen extends treatment duration and reduces breast cancer mortality further (relative risk 0.86) — with the standing reminder that low absolute risk implies low absolute benefit, so proportional reductions must be translated into the individual's absolute gain before chemotherapy is offered.^[23] Named regimens, doses, and schedules stay fenced to medical oncology — this topic claims only the proportional-benefit framework.^[22][23]

TAILORx lets the 21-gene recurrence score omit chemotherapy in node-negative disease: of 9,719 eligible patients with follow-up, 6,711 (69%) had a midrange recurrence score of 11 to 25 and were randomised to chemoendocrine therapy or endocrine therapy alone.^[24] Endocrine therapy was noninferior to chemoendocrine therapy for invasive disease-free survival (hazard ratio for invasive recurrence, second primary, or death with endocrine versus chemoendocrine therapy, 1.08), although some benefit of chemotherapy was found in some women 50 years of age or younger.^[24] Adjuvant endocrine and chemoendocrine therapy had similar efficacy in hormone-receptor-positive, HER2-negative, node-negative disease with a midrange score — with the age-50 caveat quoted, not footnoted.^[24]

MINDACT gives the 70-gene signature the same sparing role: 1,550 patients (23.2%) were at high clinical risk but low genomic risk, and at 5 years the rate of survival without distant metastasis in that group without chemotherapy was 94.7% — approximately 46% of women with breast cancer who are at high clinical risk might not require chemotherapy.^[25] Assays change management in discordant intermediate risk and are redundant at the extremes and where nodal status already mandates treatment — the clinical-risk envelope, not the assay alone, decides.^[24][25]

HER2 escalation and BRCA — KATHERINE and OlympiA

One year of trastuzumab after adjuvant chemotherapy significantly improves disease-free survival in HER2-positive disease (hazard ratio 0.54), and 1 year is the tested standard — quote the duration the trial tested, not a longer course.^[26] Residual invasive HER2-positive disease after neoadjuvant therapy is an escalation opportunity, not an accepted failure: invasive disease-free survival was significantly higher with T-DM1 than with trastuzumab (hazard ratio for invasive disease or death, 0.50), with 88.3% free of invasive disease at 3 years on T-DM1 against 77.0% on trastuzumab.^[27] The surgeon's neoadjuvant sequencing therefore interacts directly with KATHERINE-style escalation — downstage, resect, read the pathology, escalate what remains.^[27]

For germline BRCA1- or BRCA2-mutated high-risk HER2-negative early breast cancer, adjuvant olaparib delivered 3-year invasive disease-free survival of 85.9% against 77.1% on placebo (difference 8.8 percentage points; hazard ratio for invasive disease or death, 0.58).^[28] Test the high-risk HER2-negative patient for germline BRCA status early enough for the result to shape both the operation and the adjuvant plan.^[28]

Neoadjuvant window, special presentations, follow-up — fenced

The verified neoadjuvant claims in this topic are three: sentinel-node biopsy after neoadjuvant chemotherapy in cN1 disease misses more than 1 in 10 residual axillae, converting cN+ to ycN0 carries a 14.2% false-negative rate with 80.1% detection, and residual HER2-positive disease after neoadjuvant therapy escalates to T-DM1.^[18][19][27] Tumour-bed clip technique, response-adapted de-escalation rules, inflammatory-disease trimodality sequencing, pregnancy trimester safety, elderly primary-endocrine selection, male-breast defaults, surveillance schedules, and survivorship toxicities are outside this topic's verified set and stay fenced — manage them from their owning topics and guidelines, and do not import numbers this topic does not verify.^[18][27]

Exam Synthesis and Fence Map — what this topic owns

This topic owns screening numbers (USPSTF 2024 bands plus Marmot 20% and 11%), triple assessment with core-biopsy sensitivity, the 1% ER line with the ER-low caveat, the IHC 2+ reflex rule, the anatomic-versus-prognostic staging split, B-06 equivalence with the 14.3%-versus-39.2% radiotherapy effect, no-ink-on-tumour margins, DCIS and whole-breast radiotherapy numbers, the full axillary arc (B-32, Z0011 with 10-year follow-up, AMAROS with 10-year update and 24.5%-versus-11.9% lymphoedema, INSEMA, Z1071, SENTINA), EBCTCG endocrine and chemotherapy proportional reductions, TAILORx and MINDACT sparing rules, HERA 1-year trastuzumab, KATHERINE escalation, and OlympiA eligibility with benefit.^{[2][3][4][8][13][16][22][26]} Fenced out: exact TNM millimetre cutoffs and in-situ handling (AJCC manual), imaging-lexicon and MRI selection (breast imaging), margin widths for DCIS and oncoplastic or reconstructive technique (operative topics), chemotherapy regimens and endocrine schedules with toxicities (medical oncology), and pregnancy, elderly, male, inflammatory, surveillance, and survivorship detail (owning topics).^[6][9][21]

Exam pearls — the one-liners that score

• Screen biennial 40 to 74 (grade B); consent with Marmot — 20% mortality reduction invited, 11% overdiagnosis long-term.^[2][3]
• Triple assessment every lump; core biopsy 96% sensitivity beats cytology 60% — never plan definitive treatment on clinical grounds alone.^[7]
• ER 1% or more is positive; 1 to 10% is ER Low Positive with limited endocrine-benefit data — nuance, not promise.^[4]
• No ink on tumour for invasive margins; wider clearance does not lower recurrence — stop re-excising.^[9]
• B-06: survival equal across mastectomy, lumpectomy, and lumpectomy plus irradiation; radiotherapy cut ipsilateral recurrence 39.2% to 14.3%.^[8]
• Z0011: T1-T2, node-negative clinically, 1 to 2 positive sentinels, conservation plus radiotherapy — outside it, dissect.^[13]
• AMAROS 10-year: recurrence 0.93% versus 1.82%, survival tied, lymphoedema 24.5% versus 11.9% — radiotherapy preferred for sentinel-positive cT1-2.^[16]
• Post-neoadjuvant sentinel node: false-negative 12.6% (Z1071) and 14.2% (SENTINA) — Z0011 omission does not transfer.^[18][19]
• Tamoxifen helps ER-positive only (about a third off mortality over 15 years); aromatase inhibitor beats tamoxifen postmenopausally (12.1% versus 14.2% 10-year mortality).^[20][21]
• TAILORx midrange 11 to 25: endocrine alone noninferior node-negative — except some 50-or-younger benefit; MINDACT clinical-high/genomic-low 94.7% distant-metastasis-free without chemotherapy.^[24][25]
• Residual HER2-positive disease after neoadjuvant therapy escalates to T-DM1 (HR 0.50; 88.3% versus 77.0% at 3 years); germline BRCA high-risk HER2-negative escalates to olaparib (85.9% versus 77.1%).^[27][28]

References28ShowHide

1. [1]Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021.PMID 33538338
2. [2]Nicholson WK, et al. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 2024.PMID 38687503
3. [3]Independent UK Panel on Breast Cancer Screening The benefits and harms of breast cancer screening: an independent review. Lancet, 2012.PMID 23117178
4. [4]Allison KH, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol, 2020.PMID 31928404
5. [5]Wolff AC, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med, 2018.PMID 29846104
6. [6]Giuliano AE, et al. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin, 2017.PMID 28294295
7. [7]Clarke D, et al. Replace fine needle aspiration cytology with automated core biopsy in the triple assessment of breast cancer. Ann R Coll Surg Engl, 2001.PMID 11320918
8. [8]Fisher B, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med, 2002.PMID 12393820
9. [9]Moran MS, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol, 2014.PMID 24516019
10. [10]Bijker N, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol, 2006.PMID 16801628
11. [11]Darby S, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet, 2011.PMID 22019144
12. [12]Krag DN, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol, 2010.PMID 20863759
13. [13]Giuliano AE, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA, 2011.PMID 21304082
14. [14]Giuliano AE, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA, 2017.PMID 28898379
15. [15]Donker M, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol, 2014.PMID 25439688
16. [16]Bartels SAL, et al. Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial. J Clin Oncol, 2023.PMID 36383926
17. [17]Reimer T, et al. Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial. N Engl J Med, 2025.PMID 39665649
18. [18]Boughey JC, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA, 2013.PMID 24101169
19. [19]Kuehn T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol, 2013.PMID 23683750
20. [20]Davies C, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 2011.PMID 21802721
21. [21]Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet, 2015.PMID 26211827
22. [22]Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 2005.PMID 15894097
23. [23]Peto R, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet, 2012.PMID 22152853
24. [24]Sparano JA, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med, 2018.PMID 29860917
25. [25]Cardoso F, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med, 2016.PMID 27557300
26. [26]Piccart-Gebhart MJ, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 2005.PMID 16236737
27. [27]von Minckwitz G, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med, 2019.PMID 30516102
28. [28]Tutt ANJ, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med, 2021.PMID 34081848